263 results about "Ganglioside" patented technology

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, and (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

This invention relates to specific antibodies against ganglioside GD3 called MB3.6 and against protein prostate specific membrane antigen (PSMA) called 3D8, 4D4 and 3E11 when prepared as chimeric molecules with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing these antigens.

The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, they are modified in the region of the murine frameworks (FRs) and in particular in those zones that could be in an antigenic site for the T cells, so several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related with use of the antibodies for therapeutical and diagnostic purposes.

A method for preparing the Monosialotetrahexosylganglioside with high purity is provided, which comprises the following process steps: (1) the fresh brain tissue of the licestock is used to prepare the acetone powder; (2) the acetone powder prepared in the step (1) is dissolved by the extracting solution and stirred for 4h to 5h, and is separated centrifugally and collects the supernatant, the supernatant is purified by LV chromatographic column to gain the total ganglioside; (3) the total ganglioside prepared in the step (2) is separated by MonoQ column chromatography to gain the ganglioside GM1 with purity of 90 per cent to 95 per cent; (4) the GM1 prepared in the step (3) is separated by the hydrophobic chromatography to gain the ganglioside GM1 with purity more than 98 per cent; (5) the GM1 aqueous solution prepared in the step (4) is hyperfiltrated by the hyperfiltration membrane with 50,000 to 100,000 MWCO, and the gained filter liquor produces the GM1 dry powder through freezing and drying. The method not only has simple process flow and safe operation, but also can improve the yield of the GM1 and avoid the pollution of other phospholipids.

The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treat with a composition of this invention in hopes of reducing the risk of recurrence.

The invention provides infant formula milk powder for improving health of intestinal tracts, which is prepared with raw milk as a main raw material with addition of whey protein powder being rich in MFGM and other materials. By means of the novel whey protein powder being rich in MFGM as the raw material, contents of bio-active substances having special functional components, such as MFGM protein, lactoferrin, phospholipid, gangliosides, sphingomyelin, sialic acid and the like, are increased by regulation of the formula, so that the milk powder can promote colonization of probiotics in intestinal flora of infants and improves the content of immune factors in intestinal tracts and reduces intestinal disease incidence. The formula is suitable for researching on formula milk powder for infants and follow-up infants.

The monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

The invention relates to a preparation method of a nervous tissue repair scaffold loaded with dual trophic factors including ganglioside (GM1) and nerve growth factor (NGF). The method comprises the processes of constructing a preparation machine, preparing GM1 and NGF ultrapure water, preparing a hexafluoroisopropanol (HFIP) mixed solution of silk fibroin and polylactic acid-polycaprolactone (P(LLA-CL)), preparing the nanofiber scaffold loaded with the dual trophic factors including the GM1 and the NGF, and the like. The prepared nanofiber scaffold reforms a neural repair conduit through a biochemical method (namely addition of the active trophic factors) and a topological structure method (namely introduction of an oriented structure), aims to research the controlled-release behaviors and the nerve regeneration promotion function of the dual trophic factors, and can induce nerve regeneration through nanofiber orientation. The method provides experimental and theoretical basis for neural repair, and provides a new method for clinical repair of large nerve defects.

A process for preparing monosialic acid tetra-hexose ganglioside preparation from pig's brain includes such steps as ultrafilter membrane separation, chromatography by Iatrobeads column and DEAE sephadex A-25 column, and efficient liquid-phase chromatography technique. In the preparation process, it retains the GMI amphipathy physico-chemical characteristic of ganglioside. Its advantages are highpurity (more than 95%), low cost, environment protection and high curative effect.

One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

The invention relates to a medicament for nerve regeneration promotion, and particularly to a nerve regeneration promotion injection and a preparation method thereof. The nerve regeneration promotion injection is composed of the following ingredients in proportion: 280-320 micrograms of mouse nerve growth factor for injection, 19-21ml of single sialic acid four hexose ganglioside sodium injecta, 18-22ml of cerebroside-kinin injecta, 9-11ml of mecobalamine injecta and 9-11ml of dexamethasone acetate injecta. The five effective ingredients of the medicament provided by the invention are combined together and cooperative actions of multiple nutritive factors are utilized, so that the medicament has a significant curative effect on repairing of injured nerve, especially the repairing of spinal nerve injury. The medicament provided by the invention also has a protection effect on spinal cord transected injury at the early stage.